CRNX vs GS · rev $35.9M vs P/E 20, rev $58.28B
Crinetics Pharmaceuticals Inc (CRNX) versus Goldman Sachs Group Inc (GS) — a side-by-side from cached financials, not a winner call.
Crinetics Pharmaceuticals Inc (CRNX) is a biotechnology company listed on US.
Goldman Sachs Group Inc (GS) is a capital markets company listed on NYSE. It is led by David M. Solomon.
Latest reported CRNX revenue for 2026-06-30 was $35.9M. Net income was -$248.7M. CRNX currently screens at market cap $2.76B.
Latest reported GS revenue for 2025-12-31 was $58.28B. Net income was $17.18B. Revenue was up 8.9% from 2024-12-31 to 2025-12-31. GS currently screens at market cap $324.25B and trailing P/E 20.1.
CRNX currently screens at market cap $2.76B. GS currently screens at market cap $324.25B and trailing P/E 20.1.
Not investment advice. Open the CRNX and GS stock pages for the full models.
Not investment advice.